Activity Description
Ocular adverse events associated with antibody-drug conjugates are common, dose-limiting, and inadequately graded by current scales. This activity reviews corneal pseudomicrocyst pathophysiology, emerging consensus grading systems, and potential preventative strategies to improve oncology-ophthalmology coordination of care.
Sponsored by
The Fundingsland Group, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 132954, is accredited by COPE for continuing education for optometrists. This course is approved for 0.25 hours of CE.
Course # 104546-PH
Activity #: 132954
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Release Date: 05-29-2026
Expiration Date: 05-28-2027
Target Audience
This accredited educational activity is designed for optometrists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from AbbVie.
Faculty
